Sequana Medical announces positive data from non-randomized cohort in US Phase 1/2a MOJAVE study of DSR® 2.0 for treatment of heart failure
29 nov. 2023 01h00 HE
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION29 November 2023, 07:00 am CET Data from all three patients in non-randomized cohort treated with DSR 2.0 indicate safe and effective...
Sequana Medical announces results of Extraordinary General Meeting of Shareholders
10 nov. 2023 12h00 HE
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION10 November 2023, 06:00 pm CET Ids van der Weij appointed as non-executive director Ghent, Belgium – 10 November 2023 – Sequana Medical NV (Euronext Brussels:...
Sequana Medical announces additional alfapump data supporting strong and durable clinical profile; PMA on track for year-end submission
19 oct. 2023 01h00 HE
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION19 October 2023, 07:00 am CEST One-year alfapump data from POSEIDON shows safety and strong efficacy profile is maintained at 12...
Sequana Medical announces initial positive data from MOJAVE, a US Phase 1/2a study of DSR® 2.0 for treatment of heart failure through breaking vicious cycle of cardiorenal syndrome
18 oct. 2023 01h00 HE
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION18 October 2023, 07:00 am CEST First two US patients from non-randomized cohort successfully treated with DSR 2.0Initial data indicate that...
Sequana Medical announces Extraordinary General Meeting of Shareholders on 10 November 2023
06 oct. 2023 01h00 HE
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION06 October 2023, 07:00 am CEST Ghent, Belgium – 06 October 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer...
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
04 oct. 2023 12h00 HE
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION4 October 2023, 06:00 pm CEST Ghent, Belgium, 4 October 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the...
Sequana Medical announces H1 2023 results and provides business update
14 sept. 2023 01h00 HE
|
Sequana Medical NV
PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION14 September 2023, 07:00 CEST alfapump® – strong pivotal POSEIDON data presented at leading international liver congress / on track to file...
Sequana Medical Notice of 2023 Half-year Results and Business Update
06 sept. 2023 01h00 HE
|
Sequana Medical NV
Ghent, Belgium – 6 September 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure...
Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure
10 juil. 2023 01h00 HE
|
Sequana Medical NV
PRESS RELEASE US study seeking to confirm strong efficacy data reported in RED DESERT and SAHARA Initial data expected in Q4 2023 Ghent, Belgium – 10 July 2023 – Sequana Medical NV (Euronext...
1,000th alfapump® implant completed
06 juil. 2023 01h00 HE
|
Sequana Medical NV
Extensive real world alfapump experience derisks planned US & Canadian launchStrong clinical alfapump profile demonstrated in North American POSEIDON studyAll approvals received to commence US...